Dispensing error leading to alendronate ingestionCARRIERE, Benoit; BAILEY, Benoit; CHABOT, Gilles et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 1, pp 87-89, issn 1060-0280, 3 p.Article

Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial: Clinical articleNAGAHAMA, Ken; KANAYAMA, Masahiro; TOGAWA, Daisuke et al.Journal of neurosurgery. Spine. 2011, Vol 14, Num 4, pp 500-507, issn 1547-5654, 8 p.Article

Bioequivalence studies on bisphosphonates: The example of alendronateLAINESSE, Audrey; OZALP, Yildiz; HONG WONG et al.Arzneimittel-Forschung. 2004, Vol 54, Num 9A, pp 569-572, issn 0004-4172, 4 p.Article

Bone-bound bisphosphonate inhibits growth of adjacent non-bone cellsCORNISH, Jillian; BAVA, Usha; CALLON, Karen E et al.Bone (New York, NY). 2011, Vol 49, Num 4, pp 710-716, issn 8756-3282, 7 p.Article

Alendronate decorated nano hydroxyapatite in mesoporous silica: Cytotoxicity and osteogenic propertiesWEI HUANG; WEIQIANG LIU; ZHENDING SHE et al.Applied surface science. 2011, Vol 257, Num 23, pp 9757-9761, issn 0169-4332, 5 p.Article

Alendronate PLGA microspheres with high loading efficiency for dental applicationsNAFEA, Eman H; EL-MASSIK, Magda A; EL-KHORDAGUI, Labiba K et al.Journal of microencapsulation. 2007, Vol 24, Num 6, pp 525-538, issn 0265-2048, 14 p.Article

Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosisSEVCIK, Molly A; LUGER, Nancy M; MANTYH, Patrick W et al.Pain (Amsterdam). 2004, Vol 111, Num 1-2, pp 169-180, issn 0304-3959, 12 p.Article

Secondary osteoporosis: Underlying disease and the risk for glucocorticoid-induced osteoporosisBOLING, Eugene P.Clinical therapeutics. 2004, Vol 26, Num 1, pp 1-14, issn 0149-2918, 14 p.Article

Differing effects of denosumab and alendronate on cortical and trabecular boneZEBAZE, Roger M; LIBANATI, Cesar; SEEMAN, Ego et al.Bone (New York, NY). 2014, Vol 59, pp 173-179, issn 8756-3282, 7 p.Article

Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnoverPERIS, P; TORRA, M; OLIVARES, V et al.Bone (New York, NY). 2011, Vol 49, Num 4, pp 706-709, issn 8756-3282, 4 p.Article

Alendronate reduces osteoclast precursors in osteoporosisD'AMELIO, P; GRIMALDI, A; CRISTOFARO, M. A et al.Osteoporosis international. 2010, Vol 21, Num 10, pp 1741-1750, issn 0937-941X, 10 p.Article

Spectroscopic markers of bone quality in alendronate-treated postmenopausal womenBOSKEY, A. L; SPEVAK, L; WEINSTEIN, R. S et al.Osteoporosis international. 2009, Vol 20, Num 5, pp 793-800, issn 0937-941X, 8 p.Article

Adherence to alendronate in male veteransHANSEN, K. E; SWENSON, E. D; BALTZ, B et al.Osteoporosis international. 2008, Vol 19, Num 3, pp 349-356, issn 0937-941X, 8 p.Article

Alendronate-Induced SynovitisGWYNNE JONES, David P; SAVAGE, Ruth L; HIGHTON, John et al.Journal of rheumatology. 2008, Vol 35, Num 3, pp 537-538, issn 0315-162X, 2 p.Article

Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cellsDUQUE, Gustavo; RIVAS, Daniel.Journal of bone and mineral research (Print). 2007, Vol 22, Num 10, pp 1603-1611, issn 0884-0431, 9 p.Article

Alendronate treatment in women with normal to severely impaired renal function : An analysis of the fracture intervention trialJAMAL, Sophie A; BAUER, Douglas C; ENSRUD, Kristine E et al.Journal of bone and mineral research (Print). 2007, Vol 22, Num 4, pp 503-508, issn 0884-0431, 6 p.Article

Brand versus generic alendronate : Gastrointestinal effects measured by resource utilizationHALKIN, Hillel; DUSHENAT, Marina; SILVERMAN, Barbara et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 1, pp 29-34, issn 1060-0280, 6 p.Article

In vitro disintegration and dissolution and in vivo bioequivalence of two alendronate once-weekly formulationsALMEIDA, Susana; ALMEIDA, Ana; FILIPE, Augusto et al.Arzneimittel-Forschung. 2006, Vol 56, Num 2, pp 84-89, issn 0004-4172, 6 p.Article

The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatmentORNOY, Asher; WAJNBERG, Rivka; DIAV-CITRIN, Orna et al.Reproductive toxicology (Elmsford, NY). 2006, Vol 22, Num 4, pp 578-579, issn 0890-6238, 2 p.Article

In vitro and in vivo equivalence studies of alendronate monosodium tabletsROLDAN, Emilio José; QUATTROCCHI, Oscar; ZANETTI, Daniel et al.Arzneimittel-Forschung. 2005, Vol 55, Num 2, pp 93-101, issn 0004-4172, 9 p.Article

Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational studyTURBI, Carmen; HERRERO-BEAUMONT, Gabriel; ACEBES, Juan Carlos et al.Clinical therapeutics. 2004, Vol 26, Num 2, pp 245-256, issn 0149-2918, 12 p.Article

Patients with osteoporosis prefer once weekly to once daily dosing with alendronateKENDLER, David; WAI CHEE KUNG, Annie; FULEIHAN, Ghada El-Hajj et al.Maturitas (Amsterdam). 2004, Vol 48, Num 3, pp 243-251, issn 0378-5122, 9 p.Article

Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatmentMA, Yanfei L; ZENG, Qing Q; STEPAN, Jan J et al.Bone (New York, NY). 2014, Vol 59, pp 139-147, issn 8756-3282, 9 p.Article

Efficacy of Continued Alendronate for Fractures in Women With and Without Prevalent Vertebral Fracture: The FLEX TrialSCHWARTZ, Ann V; BAUER, Douglas C; BLACK, Dennis M et al.Journal of bone and mineral research (Print). 2010, Vol 25, Num 5, pp 976-982, issn 0884-0431, 7 p.Article

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal statusLANGDAHL, B. L; MARIN, F; SHANE, E et al.Osteoporosis international. 2009, Vol 20, Num 12, pp 2095-2104, issn 0937-941X, 10 p.Article